Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing 18F-FDG PET/CT SUV quantifica

1. WHO Department of Gender, Women and Health. Gender in lung cancer andsmoking research. Geneva: World Health Organization; January 2004. p. 8.Search in Google Scholar

2. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-7.10.1056/NEJMoa022136Search in Google Scholar

3. Baum RP, Hellwig D, Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med MolImaging 2004; 48: 119-42.Search in Google Scholar

4. Hellwig D, Baum RP, Kirsch C. FDG PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin 2009; 48: 59-69.10.3413/nukmed-0217Search in Google Scholar

5. Vansteenkiste J, Fisher BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004; 5: 531-40.10.1016/S1470-2045(04)01564-5Search in Google Scholar

6. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 2012; 264: 559-66.10.1148/radiol.12111148Search in Google Scholar

7. Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J, et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol 2008; 3: 130-4.10.1097/JTO.0b013e318160c122Search in Google Scholar

8. Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, et al. Standard uptake value and metabolic tumour volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2011; 38: 1628-35.10.1007/s00259-011-1838-5Search in Google Scholar

9. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, et al. (18) F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med 2011; 52: 1684-9.10.2967/jnumed.111.095257Search in Google Scholar

10. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF. Survival in earlystage non-small cell lung cancer. Ann Thorac Surg 1995; 60: 466-72.10.1016/0003-4975(95)00169-LSearch in Google Scholar

11. Gümüştaş S, Inan N, Akansel G, Ciftçi E, Demirci A, Ozkara SK. Differentiation of malignant and benign lung lesions with diffusion-weighted MR imaging. Radiol Oncol 2012; 46: 106-13.10.2478/v10019-012-0021-3347293223077446Search in Google Scholar

12. Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Physician 2007; 75: 56-63.Search in Google Scholar

13. Andrade RS, Odell DD, D’Cunha J, Maddaus MA. Endobronchial ultrasonography (EBUS)-Its role in staging of non-small cell lung cancer and who should do it? J Thorac Cardiovasc Surg 2012; 144: S9-S13.10.1016/j.jtcvs.2012.03.06822898528Search in Google Scholar

14. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th edition. New York: Springer; 2010. p. 299-324.Search in Google Scholar

15. Eisenhauera EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.Search in Google Scholar

16. Beadsmoore CJ, Screton NJ. Classification, staging and prognosis of lung cancer. Eur J Radiol 2003; 45: 8-17.10.1016/S0720-048X(02)00287-5Search in Google Scholar

17. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999; 40: 1771-7.Search in Google Scholar

18. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 2000; 27: 643-6.Search in Google Scholar

19. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV Measurements. AJR Am J Roentgenol 2010; 195: 1043.10.2214/AJR.10.492320651185Search in Google Scholar

20. Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200.10.1007/s00259-009-1297-4279147519915839Search in Google Scholar

21. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005; 130: 151-9.10.1016/j.jtcvs.2004.11.00715999056Search in Google Scholar

22. Van Baardwijk A, Dooms C, Van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007; 43: 1392-8.10.1016/j.ejca.2007.03.02717512190Search in Google Scholar

23. Sasaki R, Komaki R, Macapinlac H. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. JClin Oncol 2005; 23: 1136-43.10.1200/JCO.2005.06.12915718309Search in Google Scholar

24. Jeong HJ, Min JJ, Park JM, Kim BT, Jeong JM, Lee DS, et al. Determination of the prognostic value of [(18)F] fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl MedCommun 2002; 23: 865-70.Search in Google Scholar

25. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004; 22: 3255-60.10.1200/JCO.2004.11.10915310769Search in Google Scholar

26. Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, Hawes SE, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: New contrary data on prognostic role. ClinCancer Res 2007; 13: 3255-63.10.1158/1078-0432.CCR-06-112817545531Search in Google Scholar

27. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17: 3201-6.10.1200/JCO.1999.17.10.320110506619Search in Google Scholar

28. Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. EurJ Cardiothorac Surg 2008; 33: 819-23.10.1016/j.ejcts.2008.02.00518374589Search in Google Scholar